Combinations of iOnctura’s roginolisib revert immune suppression in immunotherapy-resistant NSCLC
-
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC
-
Data demonstrated roginolisib-containing regimens were tolerable, reduced immunosuppressive activated regulatory T cells (Tregs) and expanded stem-like CD8+ T cells
-
The ‘chemo-free’ (roginolisib plus dostarlimab) arm exhibited the most pronounced and sustained immune-cell changes and had the lowest rate of grade ≥3 adverse events; approximately half the rate of the other two ‘chemo-containing’ arms
-
Clinical benefit was observed across all arms, and overall survival follow-up is ongoing
Geneva, Switzerland and Amsterdam, The Netherlands and Cambridge, Massachusetts, USA, November 6, 2026 – iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today presented late-breaking data from PULMO-01, evaluating combinations of roginolisib in patients with immunotherapy-resistant NSCLC, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
